Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Ladenburg, Germany, 21 March 2025 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook ...
KFF Health News11h
From KFF Health News - Latest Stories:
U.S. News & World Report: Calling The Shots: Tracking Robert F. Kennedy Jr.'s Moves On Vaccines Since taking the helm of HHS, Robert F. Kennedy Jr. has both backed vaccination as a public health ...
Tivic Health targets FDA approval for Entolimod within 18 months, highlights transformation into biopharma
The company also anticipates opportunities for emergency use authorization in international markets before FDA approval. Tivic expects to leverage Entolimod for additional indications, including ...
STAT10h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
FNArena20h
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...
Novartis23h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company ...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common ...
Chattanoogan.com10hOpinion
Capitol Report From State Rep. Greg Vital For March 21
House Joint Resolution 318 urges Gov. Bill Lee and the State Capitol Commission to name a new entrance to Motlow Tunnel ...
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...
Chimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition ...